MBB Public Markets I LLC Invests $320,000 in Hologic, Inc. $HOLX

Key Points

• MBB Public Markets I LLC has initiated a new investment in Hologic, Inc., acquiring 5,180 shares valued at approximately $320,000.
• Hologic reported a quarterly earnings per share of $1.08, which surpassed analysts' expectations of $1.05, with a revenue of $1.02 billion.
• Wall Street analysts have raised their price targets for Hologic, with UBS Group increasing its target from $65.00 to $70.00 and Royal Bank Of Canada upgrading their target from $72.00 to $87.00.

MBB Public Markets I LLC bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,180 shares of the medical equipment provider's stock, valued at approximately $320,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Farther Finance Advisors LLC increased its holdings in shares of Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the period. SG Americas Securities LLC increased its holdings in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after purchasing an additional 5,172 shares during the period. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after purchasing an additional 528 shares during the period. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Hologic by 4.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after purchasing an additional 767 shares during the period. Finally, Allworth Financial LP increased its holdings in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the period. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOLX. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Evercore ISI upped their target price on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Finally, Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $78.00.

Hologic Price Performance

Shares of HOLX traded down $0.41 during trading hours on Monday, reaching $64.04. 301,750 shares of the stock traded hands, compared to its average volume of 2,643,350. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The company's 50-day moving average price is $66.43 and its two-hundred day moving average price is $62.64. The company has a market cap of $14.24 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $1.06 EPS. Hologic's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.